Miniatura

Fitxers

jcm-10-04610-v2.pdf (996.92 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-10-08

Llicència de publicació

cc by (c) Balaz, David et al, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183908

Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm10194610

Resum

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236-996) mu g/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) mu g/dL; p < 0.001), and lower Sp0(2)/Fi0(2) (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation

Matèries

COVID-19, Corticosteroides

Matèries (anglès)

COVID-19, Adrenocortical hormones

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BALAZ, David, WIKMAN-JORGENSEN, Philip erick, GALVAÑ, Vicente giner, RUBIO RIVAS, Manuel, MIGUEL CAMPO, Borja de, LÓPEZ, Mariam noureddine, LÓPEZ CALEYA, Juan francisco, GÓMEZ HUELGAS, Ricardo, PESQUEIRA FONTÁN, Paula maría, MÉNDEZ BAILÓN, Manuel, FERNÁNDEZ GARCÉS, Mar, FERNÁNDEZ CRUZ, Ana, GARCÍA GARCÍA, Gema maría, RHYMAN, Nicolás, CORRAL GUDINO, Luis, LOZANO RODRÍGUEZ-MANCHEÑO, Aquiles, CHICA, María navarro de la, TORREGROSA GARCÍA, Andrea, ALCALÁ, José nicolás, DÍAZ JIMÉNEZ, Pablo, ROYO TRALLERO, Leticia esther, COMAS CASANOVA, Pere, MILLÁN NÚÑEZ-CORTÉS, Jesús, CASAS ROJO, José manuel, SEMI-COVID-19 Network. Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry. _Journal of Clinical Medicine_. 2021. Vol.  vol 10, núm. num 19. [consulta: 30 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/183908]

Exportar metadades

JSON - METS

Compartir registre